Bevacizumab in combination with various chemotherapy protocols for treatment of advanced colorectal cancer:a clinical evaluation
LI Jie,LU Ming,LI Jian,ZHANG Xiao-tian,LI Yan,ZHANG Xiao-dong,WANG Ting-ting,SHEN Lin
2012-01-01
Abstract:Objective To determine the efficacy and safety of Bevacizumab(Bev) in combination with various chemotherapy protocols in patients with advanced colorectal cancer(mCRC). Methods Intravenous Bev(5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks) was used in combination with oxaliplatin-,irinotecan-and fluoropyrimidine-based regimens,respectively.The therapeutic efficacy was assessed every 6 months based on Response Evaluation Criterion for Solid Tumors(RECIST),and the adverse events were evaluated according to National Cancer Institute-Common Toxicity Criterion for Adverse Events(NCI-CTC AE) Ed 3.0. Results Of 54 patients(26 males and 28 females) aged 24~73(median:50) years who underwent the combination chemotherapy,16 received oxaliplatin-based regimen,32 were given irinotecan-based regimen,and 6 were treated with fluoropyrimidine-based regimen.Initial chemotherapy was performed in 22 of the patients.The therapeutic efficacy was assessable in 21 cases,among whom the response rate(RR) was 33.3%(7/21),disease control rate(DCR) 100%(21/21),median progression-free survival(PFS) time 11.3 months and overall survival(OS) duration 20.9 months.In all of the 54 cases which included 12(23.5%) of partial remission(PR),disease stability(SD) and disease progression(PD) and efficacy not applicable was found in,32(62.7%),7(13.5%) and 3 cases,respectively.The median PFS time was 8.4 months and median OS duration was 15.5 months.The major grade 3/4 adverse events were leucocytopenia(9 cases,16.7%),neutropenia(13 cases,24.1%),neutropenic febrile(1 case,1.9%).2 cases(3.8%) were reported as having grade 3 nausea/vomiting,and 3 cases(5.7%),grade 3 diarrhea.Grade 1/2 Bev-associated adverse events were proteinuria(2 cases,3.8%),hypertension(1 case,1.9%),rhinorrhagia(2 cases,3.8%),hemorrhagic hemorrhoid(1 case,1.9%). Conclusion Bev in combination with various chemotherapy protocols is effective and is not associated with worsening of adverse events in patients with mCRC.